Rheumatic complications of long term treatment with hemodialysis

Akasbi, Nessrine; Houssaïni, Tarik Sqalli; Tahiri, Latifa; Hachimi, Hicham; Maaroufi, C.; Youbi, R. El; Arrayhani, M.; Harzy, Taoufik

doi:10.1007/s00296-010-1756-z

Cited by 15 publications

(13 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 31 This observed difference could be related to be difference in eligibility criteria; in the Lebanon study, all of the participants were stage V chronic kidney disease patients, which has been a positive correlation with MSDs. 32 This discrepancy could be due to the adoption of differing definitions for musculoskeletal illnesses; in the Lebanon study, MSDs were classified according to predetermined diagnostic criteria. The difference in data collection methods could explain the discrepancy; they used a rheumatologist and additional radiographic evidence, whereas the current study used a standard Nordic musculoskeletal disorders questionnaire and chart revision from a patient’s medical record, which could explain the discrepancy.…”

Section: Discussionmentioning

confidence: 99%

Musculoskeletal Disorders and Associated Factors Among Patients with Chronic Kidney Disease Attending at Saint Paul Hospital, Addis Ababa, Ethiopia

Deme¹,

Fisseha²,

Kahsay³

et al. 2021

IJNRD

View full text Add to dashboard Cite

Background Musculoskeletal disorders contributed from chronic kidney disease are increasing worldwide. Musculoskeletal disorders had a significant health burden and are leading causes of co-morbidities, disability and low productivity, which potentially affect individual’s functional status and quality of life. Purpose The aim of this study was to assess the prevalence of musculoskeletal disorders and its associated factors among patients with chronic kidney attending in Saint Paul Hospital, Addis Ababa, Ethiopia. Patients and Methods An institution-based cross-sectional study was conducted on 302 enrolled study participants through systematic random sampling techniques. Face-to-face interview, physical examination and chart reviews were used to collect data using semi-structured questionnaire adapted from a standard Nordic Musculoskeletal Questionnaire and other literatures. Data were entered into Epi Info version 7 and exported to SPSS version 23 for analysis. Bivariate logistic regression analysis was employed with a p-value less than 0.25. Finally, those variables having a p-value less than 0.05 with 95% CI in multivariate analysis were taken as statistically significant. Results The prevalence of musculoskeletal disorders among CKD individuals was found to be 58.6% (95% CI; 53.0, 64.1). Being female (AOR = 0.49; 95% CI 0.26, 0.94), age between 40 and 49 (AOR = 3.34; 95% CI 1.07, 10.44), stage III (AOR = 0.24; 95% CI 0.06, 0.89) and stage IV (AOR = 0.24; 95% CI 0.06, 0.89) chronic kidney disease, having HTN (AOR = 7.47; 95% CI 3.47, 16.06), parathyroid hormone level ≥100 pg/mL (AOR = 0.43; 95% CI 0.21, 0.87), calcium level <8.4 mg/dl (AOR = 5.89; 95% CI 2.66, 13.56) and serum 25 hydroxy vitamin D level <20 ng/mL (AOR = 3.91; 95% CI 1.32, 11.56) were significantly associated with musculoskeletal disorders. Conclusion MSDs were shown to be moderately common in CKD patients. Female gender, age between 40 and 49 yrs, stage III and stage IV CKD, hypertension, higher PTH level, lower calcium level and lower vitamin D level were statistically significant in their association with musculoskeletal disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Musculoskeletal Disorders and Associated Factors Among Patients with Chronic Kidney Disease Attending at Saint Paul Hospital, Addis Ababa, Ethiopia

Deme¹,

Fisseha²,

Kahsay³

et al. 2021

IJNRD

View full text Add to dashboard Cite

show abstract

“…MSK manifestations are common in patients on long-term HD, with reported frequency up to 70% [ 19 ], most of which are attributable to amyloid deposition [ 19 ]. Amyloid deposits in a variety of tissues, with a higher proclivity for bone and synovial membranes.…”

Section: Discussionmentioning

confidence: 99%

Ultrasonographic assessment of entheseal sites of upper and lower extremities in hemodialysis patients using Madrid Sonography Enthesitis Index

Sabry

Tharwat

Nassar

et al. 2022

BMC Musculoskelet Disord

View full text Add to dashboard Cite

Background There is no much information about the entheseal involvement among hemodialysis (HD) patients. The aim of this study was to assess the frequency and distribution of ultrasonographic (US) entheseal alterations in HD patients and to evaluate the association between US abnormalities and both clinical and laboratory data. Methods This study was conducted on 41 HD patients and 23 sex- and age- matched controls. All participants were evaluated clinically for any signs of enthesopathy. Six entheses sites were scanned bilaterally using grey scale (GS) and power Doppler (PD) US and were scored using Madrid Sonography Enthesitis Index (MASEI) scoring system. Results In HD patients, at least one clinical sign suggestive of enthesopathy was found in 69 (14%) of 492 entheses. HD patients had statistically significant higher scores of structural tendon abnormalities (p < 0.001), enthesis thickening (p < 0.001), bone erosions (p < 0.001) and calcification (p = 0.037) than the healthy controls. Total MASEI score was higher in HD patients than healthy controls (median;18 vs 8, p < 0.001), also, MASEI-inflammatory (median;11 vs 3, p < 0.001) and damage scores (median;6 vs 0, p < 0.001). There was a statistically significant positive association between total MASEI score and both age (p = 0.032) and duration of HD (p = 0.037). Duration of HD was predictive for both MASEI-damage component (p = 0.004) and total MASEI score (p = 0.014). Conclusion There is a high prevalence of subclinical enthesopathy in HD patients. The entheseal US alterations is much higher in HD patients than in healthy subjects. The duration of HD is the significant predictor of enthesopathy in HD patients.

show abstract

“…Interestingly, the connections with cirrhosis are variable among different rheumatic disorders. For example, the overall incidences of cirrhosis were reported to be lower in the RA cohort than in the non-RA cohort [43][44], while patients with psoriasis were found to have increased risk of cirrhosis than patients without psoriasis [44].With regard to ESRD and DM, in contrast to their negative associations with the rheumatic disorder risks, chronic kidney disease is a common complication of rheumatic disorders [45], patients undergoing hemodialysis therapy may develop serious rheumatic complications [46], newly diagnosed RA patients are at higher risk of DM [47] and the prevalence of DM is higher in patients with psoriatic arthritis compared with the general population [48]. That rheumatic disorders might be mistaken as ESRD-or DM-related complications in patients with ESRD and DM potentially explains the paradox.…”

Section: Discussionmentioning

confidence: 99%

Interferon-based therapy did not attenuate hepatitis C-associated rheumatic disorder risk: A nationwide population-based cohort study

Cheng¹,

Hu²,

Lin³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundWhether hepatitis C virus (HCV) infection increases the risk of rheumatic disorders and whether the associated risk is reversed by anti-HCV therapy remain elusive. We aimed to investigate these topics. MethodsA nationwide population-based cohort study of Taiwan National Health Insurance Research Database (TNHIRD) was conducted. ResultsOf 19,298,735 subjects, 3 TNHIRD cohorts (1:4:4, propensity score-matched), including HCV-treated (6,919 HCV-infected subjects with interferon and ribavirin therapy > 6 months), HCV-untreated (n=27,676) and HCV-uninfected (n=27,676) cohorts, were enrolled and had been followed since 2003 to 2015. HCV-uninfected cohort had the lowest 11-year cumulative incidence of rheumatic disorders [9.535%; 95% confidence interval (CI): 8.416~10.734%] (p<0.0001), while HCV-treated (14.95%; 12.417~17.704%) and HCV-untreated (14.999%; 13.585~16.479%) cohorts showed no difference in the cumulative incidences of rheumatic disorders (p=0.8316). Multivariate analyses showed, HCV infection [hazard ratio (HR):1.671; 95% CI HR: 1.562-1.788, p<0.0001], female sex (1.67; 1.565-1.782, p<0.0001), age> 49 years (1.168; 1.088-1.253, p<0.0001), Charlson comorbidity index > 1 (1.156; 1.074-1.245, p=0.0001), liver cirrhosis (0.795; 0.674-0.937, p=0.0062), chronic obstruction pulmonary disease (1.244; 1.134-1.364, p<0.0001), end stage renal disease (0.732; 0.549-0.974, p=0.0326), diabetes mellitus (0.91; 0.835-0.993, p=0.0333) and dyslipidemia (1.205; 1.108-1.31, p<0.0001) were associated with incident rheumatic disorders. Among the 3 cohorts, the untreated cohort had the highest cumulative incidence of overall mortality (29.163%; 27.218-31.133%, p<0.0001), while the treated (13.662%; 11.389-16.140%) and un-infected (9.99%; 8.548-11.559%) cohorts had indifferent mortalities (p=0.1796). ConclusionsHCV infection, baseline demographics and comorbidities were associated with the risks of rheumatic disorders. Although HCV-associated risk of rheumatic disorders might not be reversed by interferon-based anti-HCV therapy, which reduced the overall mortality in HCV-infected patients.

show abstract

Rheumatic complications of long term treatment with hemodialysis

Cited by 15 publications

References 19 publications

Musculoskeletal Disorders and Associated Factors Among Patients with Chronic Kidney Disease Attending at Saint Paul Hospital, Addis Ababa, Ethiopia

Musculoskeletal Disorders and Associated Factors Among Patients with Chronic Kidney Disease Attending at Saint Paul Hospital, Addis Ababa, Ethiopia

Ultrasonographic assessment of entheseal sites of upper and lower extremities in hemodialysis patients using Madrid Sonography Enthesitis Index

Interferon-based therapy did not attenuate hepatitis C-associated rheumatic disorder risk: A nationwide population-based cohort study

Contact Info

Product

Resources

About